FindTrial
Sign In

Autologous BAFFR-targeting CAR T Cells

BIOLOGICAL2 trials

Sponsors

Mayo Clinic, City of Hope Medical Center

Conditions

B-Cell Non-Hodgkin LymphomaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma

Phase 1

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RecruitingNCT06191887
Mayo ClinicB-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma +12
Start: 2024-03-18End: 2040-12-31Target: 27Updated: 2026-02-13
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Not yet recruitingNCT07758673
City of Hope Medical CenterRecurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia +1
Start: 2027-04-17End: 2028-07-26Target: 16Updated: 2026-08-11